Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07176923 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CS-121 APOC3 Base Editing in FCS

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2025 to Oct 15, 2025
    • Site details revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia syndrome (FCS).
Trial Details
NCT Number NCT07176923
Lead Sponsor CorrectSequence Therapeutics Co., Ltd
Collaborators: The First Affiliated Hospital of Anhui Medical University
Conditions
(from sponsor)		 Familial Chylomicronemia Syndrome (FCS)
Related terms [OBSOLETE] Familial hyperchylomicronemia syndrome, Hypertriglyceridemia, Pancreatitis
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov